RecruitingNot ApplicableNCT07384013
Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs
Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs
Sponsor
Rambam Health Care Campus
Enrollment
30 participants
Start Date
Nov 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Adult oncology patients (≥18 years old).
- Receiving apixaban or rivaroxaban for anticoagulation.
- New/current metamizole users taking at least 1g TID for pain management.
- Platelets ≥100×10⁹/L
- ECOG PS\<3
- Provided informed consent
Exclusion Criteria2
- History of allergic reaction to metamizole or DOACs.
- Individuals with significant gastrointestinal disorders that may affect absorption, including (but not limited to) diagnosed bowel obstruction, persistent diarrhea, or the presence of a nasogastric tube (NGT/zonda)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGmetamizole
chronic metamizole use
DRUGmetamizole
New metamizole users
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07384013
Related Trials
Recto-intercostal Fascial Plane Block in Cholecystectomy
NCT075028331 location
Does Patient Testimonial Improve the Pain Relief Derived From a Brief Intervention
NCT073351591 location
Pain in Aging Former Athletes, Master's Athletes, and Nonathletes
NCT075027421 location
Ultrasound-Guided Quadro-Iliac Plane Block for Pain Management After Total Hip Arthroplasty
NCT074100001 location
Prospective Study to Determine the Prevalence of Signs of Central Sensitization in Adults With ASD Without Intellectual Developmental Disorders
NCT074957611 location